4.6 Article

Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models

期刊

ACS CHEMICAL NEUROSCIENCE
卷 12, 期 11, 页码 1885-1893

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.0c00790

关键词

PET; imaging; tau; neurodegeneration; mouse; rat

资金

  1. UK Medical Research Council [MR/K02308X/1]
  2. UK Engineering and Physical Science Council [EP/P008224/1]
  3. EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking [116060]
  4. National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
  5. EPSRC [EP/P008224/1] Funding Source: UKRI
  6. MRC [MR/K02308X/1] Funding Source: UKRI

向作者/读者索取更多资源

Aggregated tau protein is a core pathology in neurodegenerative diseases, and PET imaging radiotracers that bind to tau fibrils are important for understanding these disorders. The compound LM229 from a novel library based on PBB3 backbone shows high affinity and specificity for tau aggregates in various animal models and human brain sections. LM229 can also cross the blood-brain barrier and be effectively radiolabeled with carbon-11, making it a promising tool for PET translational studies using rodent transgenic tau models.
Aggregated tau protein is a core pathology present in several neurodegenerative diseases. Therefore, the development and application of positron emission tomography (PET) imaging radiotracers that selectively bind to aggregated tau in fibril form is of importance in furthering the understanding of these disorders. While radiotracers used in human PET studies offer invaluable insight, radiotracers that are also capable of visualizing tau fibrils in animal models are important tools for translational research into these diseases. Herein, we report the synthesis and characterization of a novel library of compounds based on the phenyl/pyridinyl-butadienylbenzothiazoles/benzothiazolium (PBB3) backbone developed for this application. From this library, we selected the compound LM229, which binds to recombinant tau fibrils with high affinity (K-d = 3.6 nM) and detects with high specificity (a) pathological 4R tau aggregates in living cultured neurons and mouse brain sections from transgenic human P301S tau mice, (b) truncated human 151-351 3R (SHR24) and 4R (SHR72) tau aggregates in transgenic rat brain sections, and (c) tau neurofibrillary tangles in brain sections from Alzheimer's disease (3R/4R tau) and progressive supranuclear palsy (4R tau). With LM229 also shown to cross the blood-brain barrier in vivo and its effective radiolabeling with the radioisotope carbon-11, we have established a novel platform for PET translational studies using rodent transgenic tau models.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据